Equity Components [Axis] Preferred Stock [Member] Class of Stock [Axis] Series S Preferred Stock [Member] Common Stock [Member] Common Stock To Be Issued [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Debt Instrument [Axis] Accredited Investor 1800 Diagonal Lending [Member] Accredited Investor 1800 Diagonal Lending Note 2 [Member] Accredited Investor 1800 Diagonal Lending Note 3 [Member] Vanquish Funding Group [Member] Accredited Investor [Member] Accredited Investor 1800 Diagonal Lending Notes [Member] Steel Giant Advisors [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Warrants and Rights Subject to Mandatory Redemption [Member] Statement of Income Location, Balance [Axis] (Deprecated 2026) General and Administrative Expense [Member] (Deprecated 2026) Research and Development Expense [Member] (Deprecated 2026) Other Commitments [Axis] Drug Supplier Project Plan [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets Cash Prepaid drug product Other current assets Total current assets Right of use operating assets Total Assets Liabilities & Shareholders' (Deficit) Equity Current liabilities Accounts payable Notes payable Accrued expenses Derivative liabilities Lease liabilities Total current liabilities Warrant liability Total Liabilities Shareholders' (deficit) equity Preferred stock, $.001 par value; 10,000 shares authorized; 51 and 0 shares issued and outstanding, respectively Common stock, $.001 par value; 200,000 shares authorized; 9,242 and 5,768 shares issued and outstanding, respectively Common stock to be issued Additional paid in capital Accumulated deficit Total shareholders' (deficit) equity Total Liabilities & Shareholders' (Deficit) Equity Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized [custom:CommonStockSharesIssuedEstimated-0] [custom:CommonStockSharesOutstandingEstimated-0] Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Operating expenses Research and development General and administrative Total operating expenses Net operating income (loss) Other income (expense) Change in fair value of derivatives Gain on debt settlement Interest expense Total other income (expense) Net loss Net loss per share, basic and diluted Basic and diluted weighted average number of common shares outstanding Statement of Cash Flows [Abstract] Cash flow from operating activities Adjustments to reconcile net loss to net cash used in operating activities Stock-based compensation Amortization of debt issuance costs Amortization of right of use assets Loss (gain) on debt conversions Depreciation Change in fair value of warrant liability Change in fair value of derivative liability (Increase) decrease in operating assets Prepaid drug product Other current assets Increase (decrease) in operating liabilities Accounts payable and accrued expenses Lease liabilities Net cash used in operating activities Cash flow from financing activities Net proceeds from exercise of pre-funded warrants Proceeds from promissory notes Net cash provided by financing activities Net increase (decrease) in cash Cash, beginning of period Cash, end of period Supplemental disclosure of non-cash activities Right of use asset recognized in exchange for lease obligation Statement [Table] Statement [Line Items] Beginning balance, value Shares, Issued Exercise of pre-funded warrants, net of fees Stock Issued During Period, Shares, Conversion of Convertible Securities Stock-based compensation Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Issuance of stock to be issued Stock Issued During Period, Shares, New Issues Issuance of Series S Preferred stock Stock Issued During Period, Shares, Other Ending balance, value Shares, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] 1. Organization and Business Accounting Policies [Abstract] 2. Significant Accounting Policies Health Care Organizations [Abstract] 3. Prepaid Drug Product Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] 4. Other Current Assets Payables and Accruals [Abstract] 5. Accounts Payable Debt Disclosure [Abstract] 6. Notes Payable 7. Accrued Expense Derivative Instruments and Hedging Activities Disclosure [Abstract] 8. Warrant Liability Fair Value Disclosures [Abstract] 9. Fair Value Measurements Equity [Abstract] 10. Stockholders’ Equity Share-Based Payment Arrangement [Abstract] 11. Stock-Based Compensation Plan Commitments and Contingencies Disclosure [Abstract] 12. Commitments and Contingencies Subsequent Events [Abstract] 13. Subsequent Events Net Loss Per Share Liquidity Segment Reporting Warrants Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] 9. Fair Value Measurements - Changes to Fair Value of Level Warrants 9. Fair Value Measurements - Change to Fair Value of Level 3 Deritivative Liabilities 9. Fair Value Measurements - Black-Scholes Valuation Model Estimating Fair Value 11. Stock-Based Compensation Plan - Option Activity [custom:PrepaidExpenseCurrentEstimated-0] [custom:OtherAssetsCurrentEstimated-0] [custom:PrepaidDelawareFranchiseTaxExpenses-0] [custom:AccountsPayableCurrentEstimated-0] [custom:ClinicalTrialExpensesPayable-0] [custom:LegalAndPatentFeesPayable-0] [custom:PayableDrugManufacturingDevelopmentAndTestingServices-0] [custom:PublicCompanyRegistrationAndFilingFeesPayable-0] [custom:ProfessionalAndConsultingFeesPayable-0] Short-Term Debt [Table] Short-Term Debt [Line Items] [custom:NotesPayableCurrentEstimated-0] Short-Term Debt Proceeds from Short-Term Debt Participating Mortgage Loans, Unamortized Debt Discount, Amount [custom:PeriodicPaymentOnNoteAugust2025] [custom:PeriodicPaymentOnNoteStartingSeptember2025] [custom:PeriodicPaymentOnNoteSeptember2025] [custom:PeriodicPaymentOnNoteStartingOctober2025] Debt Instrument, Face Amount Debt Instrument, Unamortized Discount Debt Instrument, Periodic Payment [custom:PeriodicPaymentOnNoteStartingJuly2026] [custom:PeriodicPaymentOnNoteStartingAugust2026] [custom:ShortTermDebtEventOfDefaultPercentageOfOutstandingPrincipalImmediatelyDue] [custom:ShortTermDebtEventOfDefaultInterestPercentage] [custom:ShortTermDebtDefaultPenalty-0] Derivative Liability, Current [custom:AccruedLiabilitiesCurrentEstimated-0] [custom:AccruedClinicalTrialExpenses-0] [custom:AccruedEmployeeSalaryAndBenefitExpenses-0] Other Accrued Liabilities, Current Accrued Vacation, Current [custom:WarrantsAndRightsOutstandingEstimated-0] Warrants and Rights Outstanding [custom:FairValueAdjustmentOfWarrantsEstimated] Professional Fees Class of Warrant or Right, Exercise Price of Warrants or Rights Fair Value, off-Balance-Sheet Risk [Table] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Derivative Liability [custom:WarrantAndDerivativeLiability-0] Fair Value Adjustment of Warrants Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Liabilities, Fair Value Adjustment [custom:WarrantMeasurementInputRiskFreeInterestRate-0] [custom:WarrantMeasurementInputExpectedVolatility-0] [custom:WarrantMeasurementInputExpectedTermMinimum] [custom:WarrantMeasurementInputExpectedTermMaximum] [custom:WarrantMeasurementDividendYield-0] Stock, Class of Stock [Table] Class of Stock [Line Items] Class of Warrant or Right, Number of Securities Called by Warrants or Rights [custom:StockholdersEquityEstimated-0] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Payment Arrangement, Expense Other Commitments [Table] Other Commitments [Line Items] Other Commitment [custom:OtherCommitmentsDrugTestingServices-0] Other Commitment, to be Paid, Year One Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) InterestExpense2 Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Current Assets Increase (Decrease) in Operating Lease Liability Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Shares, Issued Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture